Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib

INTRODUCTION: Bone metastases are frequent in patients with EGFR-mutated (EGFR+) NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE in osimertinib-treated patients are reported. We investigated the development of bone metastases and SREs in patients with EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Brouns, Anita J.W. M., van Veelen, Ard, Veerman, G. D. Marijn, Steendam, Christi, Dursun, Safiye, van der Leest, Cor, Croes, Sander, Dingemans, Anne-Marie C., Hendriks, Lizza E.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165134/
https://www.ncbi.nlm.nih.gov/pubmed/37168878
http://dx.doi.org/10.1016/j.jtocrr.2023.100513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165134/
https://www.ncbi.nlm.nih.gov/pubmed/37168878
http://dx.doi.org/10.1016/j.jtocrr.2023.100513

Ejemplares similares